Twist Bioscience Co. (NASDAQ:TWST) Position Increased by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans raised its position in shares of Twist Bioscience Co. (NASDAQ:TWST) by 54.6% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 1,505,753 shares of the company’s stock after buying an additional 532,040 shares during the period. Thrivent Financial for Lutherans’ holdings in Twist Bioscience were worth $69,972,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of TWST. State Street Corp lifted its stake in Twist Bioscience by 19.9% during the third quarter. State Street Corp now owns 3,167,353 shares of the company’s stock valued at $143,101,000 after buying an additional 526,028 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Twist Bioscience by 188.5% in the third quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock worth $36,042,000 after purchasing an additional 521,272 shares in the last quarter. Jennison Associates LLC lifted its position in shares of Twist Bioscience by 80.2% in the fourth quarter. Jennison Associates LLC now owns 680,778 shares of the company’s stock worth $31,636,000 after purchasing an additional 302,884 shares in the last quarter. ARK Investment Management LLC lifted its position in shares of Twist Bioscience by 4.4% in the fourth quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company’s stock worth $260,040,000 after purchasing an additional 237,772 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its position in shares of Twist Bioscience by 81.9% in the fourth quarter. Principal Financial Group Inc. now owns 374,551 shares of the company’s stock worth $17,405,000 after purchasing an additional 168,687 shares in the last quarter.

Insider Activity

In related news, CEO Emily M. Leproust sold 2,402 shares of the stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $40.91, for a total transaction of $98,265.82. Following the completion of the sale, the chief executive officer now directly owns 662,692 shares of the company’s stock, valued at approximately $27,110,729.72. This represents a 0.36 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Adam Laponis sold 5,886 shares of the stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $43.26, for a total value of $254,628.36. Following the sale, the chief financial officer now directly owns 110,096 shares of the company’s stock, valued at approximately $4,762,752.96. The trade was a 5.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 33,804 shares of company stock valued at $1,601,404 in the last ninety days. 3.01% of the stock is owned by insiders.

Twist Bioscience Stock Down 4.2 %

Shares of NASDAQ TWST opened at $40.57 on Wednesday. The firm’s 50-day simple moving average is $45.54 and its 200 day simple moving average is $45.25. The company has a market cap of $2.42 billion, a price-to-earnings ratio of -12.00 and a beta of 2.15. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a 12-month low of $27.41 and a 12-month high of $60.90.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.09. The firm had revenue of $88.70 million during the quarter, compared to analysts’ expectations of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company’s quarterly revenue was up 24.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.75) EPS. On average, research analysts expect that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on TWST. TD Cowen reissued a “buy” rating and issued a $58.00 price target on shares of Twist Bioscience in a research report on Tuesday, November 26th. Barclays set a $58.00 price target on shares of Twist Bioscience and gave the stock an “overweight” rating in a research report on Monday, February 3rd. JPMorgan Chase & Co. raised their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a research report on Tuesday, February 4th. Robert W. Baird raised their price objective on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research report on Tuesday, February 4th. Finally, Wolfe Research began coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $54.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.